Multicenter PhaseII trial of continuous gefitinib for elderly patients with EGFR sensitive mutation who failed the first gefitinib treatment for advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Gefitinib (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 May 2016 Status changed from recruiting to completed.
- 01 Jun 2012 New trial record